C4 Therapeutics Inc (NAS:CCCC)
$ 4.14 -0.16 (-3.72%) Market Cap: 292.24 Mil Enterprise Value: 114.63 Mil PE Ratio: 0 PB Ratio: 1.20 GF Score: 60/100

C4 Therapeutics Inc CFT8919 Pre-Clinical Data Call Transcript

Jun 07, 2021 / 12:00PM GMT
Release Date Price: $41.45 (+6.17%)
Kendra Adams;
C4 Therapeutics, Inc. - SVP of Communications & IR

Good morning, everyone, and welcome to the C4 Therapeutics webcast to review new preclinical data for our EGFR degrader, CFT8919, being presented at the Keystone Symposium on Targeted Protein Degradation.

With me on the call today with prepared remarks are Andrew Hirsch, our Chief Executive Officer; and Dr. Adam Crystal, our Chief Medical Officer. Dr. Stew Fisher, our Chief Scientific Officer, will join for Q&A.

Before we get started, I would like to remind everyone that some of the statements we make on this call will include forward-looking statements. Actual events and results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors including those set forth in the most recent filings with the SEC and any future filings that we may make with the SEC.

Following our prepared remarks, we will have time for a Q&A session. (Operator Instructions) With that, I'll turn the call over to Andrew.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot